Moshe Giladi currently serves as Novocure’s Chief Science Officer, where he oversees Novocure’s preclinical research organization and manages external research partnerships and Novocure’s biostatistics and data management teams. Mr. Giladi joined Novocure in 2005 and most recently held the title of Senior Vice President of Preclinical Research, overseeing a team dedicated to deepening understanding and driving acceptance of Tumor Treating Fields therapy. He holds a Ph.D. in Microbiology and Biochemistry and a master’s degree in business administration from Tel Aviv University.See all leaders
Moshe Giladi, Ph.D.
Chief Science Officer